s_150324_8a
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- e1_e2
- E2
- umap1_2d
- -5.776499441
- umap2_2d
- 1.447719249
- umap1_3d
- 0.7602707
- umap2_3d
- 3.828302718
- umap3_3d
- -0.451609222
- dataset
- EPN-Heidelberg
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.420
- MYC_TARGETS_V2+0.400
- OXIDATIVE_PHOSPHORYLATION+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.350
- PANCREAS_BETA_CELLS+0.330
- MYC_TARGETS_V1+0.320
- FATTY_ACID_METABOLISM+0.310
- PEROXISOME+0.300
- INTERFERON_ALPHA_RESPONSE+0.280
- PROTEIN_SECRETION+0.280
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.370
- ANGIOGENESIS-0.330
- TGF_BETA_SIGNALING-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- KRAS_SIGNALING_DN-0.210
- TNFA_SIGNALING_VIA_NFKB-0.210
- NOTCH_SIGNALING-0.190
- ESTROGEN_RESPONSE_EARLY-0.180
- SPERMATOGENESIS-0.180
- APICAL_SURFACE-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s_150324_7a | EPN | Supratentorial EPN | 0.990 |
| 2 | MNG510 | — | — | 0.796 |
| 3 | SRR17866853 | — | — | 0.788 |
| 4 | ERR2278852 | — | — | 0.784 |
| 5 | SRR6013565 | — | cohortA4 | 0.783 |
| 6 | SRR1797278 | — | cohortSC | 0.782 |
| 7 | SRR12696791 | — | — | 0.782 |
| 8 | SRR11296765 | — | — | 0.774 |
| 9 | AUR-ADCB-TTM1-A-1-1-R-A742-41 | — | C | 0.773 |
| 10 | TCGA-AO-A03O-01A-11R-A00Z-07 | — | C | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |